Topotecan and liposomal doxorubicin in recurrent ovarian cancer: Is sequence important? Journal Article

Authors: Dupont, J.; Aghajanian, C.; Andrea, G.; Lovegren, M.; Chuai, S.; Venkatraman, E.; Hensley, M.; Anderson, S.; Spriggs, D.; Sabbatini, P.
Article Title: Topotecan and liposomal doxorubicin in recurrent ovarian cancer: Is sequence important?
Abstract: A variety of agents have emerged to treat patients with recurrent epithelial ovarian cancer (EOC). Most patients receive both topotecan (T) and liposomal doxorubicin (D); however, there are no data regarding the benefit of a sequence - D followed by T (DT) or T followed by D (TD). We identified 89 consecutive patients with recurrent EOC, who received both D and T from January 1994 to January 2004 at Memorial Hospital. We compared the duration of treatment, toxicity, and overall survival (OS) for patients who received either DT or TD. Sixty-four patients received DT, and 25 patients received TD. The groups were balanced regarding age, stage, surgical debulking, platinum sensitivity, prior therapy, and intervening drugs between D and T. Median numbers of cycles on DT and TD were seven and six, respectively (P= 0.61); there was no difference in duration based on platinum sensitivity. Removal from therapy for toxicity was similar, DT (22%) and TD (36%) (P= 0.18). Finally, there was no difference in median OS based on sequence, DT (18.28 months) and TD (17.75 months) (P= NS). Platinum sensitivity did not affect median OS based on sequence. Based on duration, toxicity, and OS there is no advantage of one sequence of D and T when treating patients with recurrent EOC. © 2006, IGCS.
Keywords: adult; cancer chemotherapy; cancer survival; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; major clinical study; overall survival; doxorubicin; treatment duration; cancer patient; topotecan; recurrent cancer; adenocarcinoma; ovarian cancer; cytoreductive surgery; ovarian neoplasms; drug eruption; neoplasm recurrence, local; bone marrow suppression; antineoplastic combined chemotherapy protocols; drug administration schedule; drug resistance, neoplasm; hospital; disease severity; ovary carcinoma; platinum; platinum compounds; drug sensitivity; liposomal doxorubicin; sequencing
Journal Title: International Journal of Gynecological Cancer
Volume: 16
Issue: Suppl.1
ISSN: 1048-891X
Publisher: Lippincott Williams & Wilkins  
Date Published: 2006-02-01
Start Page: 68
End Page: 73
Language: English
DOI: 10.1111/j.1525-1438.2006.00467.x
PUBMED: 16515570
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 4 June 2012" - "CODEN: IJGCE" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Venkatraman Ennapadam Seshan
    285 Seshan
  2. Shaokun Chuai
    29 Chuai
  3. Jakob Dupont
    64 Dupont
  4. Paul J Sabbatini
    201 Sabbatini
  5. Martee L Hensley
    220 Hensley
  6. David R Spriggs
    314 Spriggs
  7. Gabrielle Fawkner Andrea
    1 Andrea